You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 12, 2025

Belimumab - Biologic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


Summary for belimumab
Tradenames:1
High Confidence Patents:0
Applicants:1
BLAs:2
Suppliers: see list1
Recent Clinical Trials: See clinical trials for belimumab
Recent Clinical Trials for belimumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Nanjing University School of MedicinePhase 3
Assistance Publique - Hôpitaux de ParisPhase 3
Peking University People's HospitalPhase 3

See all belimumab clinical trials

Pharmacology for belimumab
Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

  1. Brand-side disclosures in response to biosimilar applications
  2. These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

  3. General brand-side disclosures
  4. These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

  5. Patents from broad patent text search
  6. For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for belimumab Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for belimumab Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for belimumab Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory of Belimumab

Introduction to Belimumab

Belimumab, a monoclonal antibody, is primarily used in the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases. Its market dynamics are influenced by several key factors, including increasing disease prevalence, regulatory approvals, and advancements in medical research.

Market Size and Forecast

The belimumab market is projected to experience significant growth. As of 2023, the market size was valued at USD 2.2 billion and is expected to reach USD 4.3 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period of 2024-2031[1].

Key Market Drivers

Increasing Prevalence of Autoimmune Diseases

The rising incidence of autoimmune diseases, particularly SLE, is a major driver for the belimumab market. As awareness and diagnosis of these conditions increase, the demand for effective therapies like belimumab is expected to rise[1].

Growing Awareness and Diagnosis

Enhanced awareness among healthcare professionals and patients has led to increased diagnosis rates, which can boost the market for treatment options like belimumab[1].

Efficacy of Belimumab

The demonstrated efficacy of belimumab in reducing disease activity and improving patient outcomes in clinical studies, such as the BLISS-52 and BLISS-76 trials, drives its adoption in treatment protocols[4].

Regulatory Approvals and Expansions

Continued approval for new indications beyond lupus, such as granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), opens new market opportunities for belimumab[1].

Advancements in Medical Research

Ongoing research into the mechanisms of lupus and autoimmune diseases may lead to new formulations, combination therapies, or innovative treatments incorporating or complementing belimumab[1].

Shift towards Personalized Medicine

A growing trend towards personalized medicine approaches may enhance the use of biologics like belimumab, which can be tailored to specific patient needs based on genetic and biomarker profiles[1].

Market Penetration and Product Availability

Increased availability of belimumab globally, driven by market entry into emerging markets and the introduction of biosimilars, can lead to enhanced sales. This is particularly evident in regions like North America, Europe, and the Asia-Pacific, where healthcare infrastructure and market access are improving[1][3].

Healthcare Infrastructure and Investment

Improvements in healthcare infrastructure and increased investment in research and development (R&D) within pharmaceutical companies can support further growth in the belimumab market. Countries with well-established healthcare systems, such as the United States, Germany, and the UK, are expected to drive this growth[1].

Patient Support Programs

Effective patient assistance and support programs from manufacturers that enhance treatment adherence can also drive market growth. These programs help in managing the regular administration of belimumab, which is crucial for its long-term efficacy[1].

Pricing and Reimbursement Policies

Favorable pricing strategies and reimbursement policies can affect market access and patient uptake of belimumab. However, the high cost associated with the drug, estimated at $40,000 in the first year and $35,000 in subsequent years in the USA, can be a significant barrier[4].

Geographical Market Variability

The acceptance and uptake of belimumab vary significantly across different geographical markets due to local healthcare practices, economic conditions, and cultural attitudes toward treatment. North America, particularly the United States, dominates the market due to its well-developed healthcare infrastructure and high prevalence of autoimmune diseases. The Asia-Pacific region, especially emerging economies like India and China, presents significant growth opportunities despite challenges such as pricing pressures and differing regulatory practices[1][3].

Budget Impact and Cost-Effectiveness

Studies have evaluated the budget impact and cost-effectiveness of belimumab. For instance, a Dutch study found that the total budget impact of belimumab subcutaneous (SC) over three years resulted in an expenditure of approximately €3.7 million, indicating increased expenditure compared to standard care but with potential long-term benefits in reducing flare management and adverse event costs[2].

A cost-effectiveness analysis in the Italian setting showed that belimumab added to standard care resulted in an Incremental Cost-Effectiveness Ratio (ICER) of €22,990 and an Incremental Cost-Utility Ratio (ICUR) of €32,859 per Quality Adjusted Life Year (QALY), suggesting that while belimumab is costly, it can provide significant health benefits[4].

Challenges and Limitations

Side Effects and Adverse Reactions

The risk of side effects and adverse reactions, such as nausea, diarrhea, vomiting, stomach pain, dizziness, insomnia, and fever, can deter physicians from prescribing belimumab, particularly if patients have concerns about the safety profile of biologics[3].

Emerging Treatments

Ongoing research and development may lead to the introduction of new therapies that could outperform belimumab, impacting its market viability. The dynamic nature of autoimmune disease treatment means that new treatments could potentially replace or complement belimumab[1].

Patient Adherence

Belimumab requires regular administration (subcutaneous or intravenous), and patient adherence to such treatment regimens can be a challenge, affecting long-term market growth. Effective patient support programs are crucial in managing this aspect[1].

Market Segmentation

The belimumab market is segmented by demographic (adult, pediatric), application (lupus nephritis, systemic lupus erythematosus, others), dosage form (injection, powder, lyophilized, solution), route of administration (intravenous, subcutaneous), end-users (clinic, hospital, others), and distribution channel (hospital pharmacy, retail pharmacy, online pharmacy)[3].

Regional Market Analysis

  • North America: Dominates the market due to a well-established healthcare system, high prevalence of autoimmune diseases, and strong R&D initiatives.
  • Europe: Substantial demand driven by advanced medical infrastructure and proactive health policies, though market penetration varies by country.
  • Asia-Pacific: Emerging economies like India and China present significant growth opportunities despite challenges.
  • Middle East and Africa: Limited access to healthcare resources but growing interest in advanced treatments[1][3].

Key Takeaways

  • The belimumab market is expected to grow significantly, driven by increasing disease prevalence and regulatory approvals.
  • The market is influenced by factors such as efficacy, patient support programs, and healthcare infrastructure.
  • Cost-effectiveness analyses indicate that while belimumab is expensive, it provides significant health benefits.
  • Challenges include side effects, emerging treatments, and patient adherence.
  • Market segmentation and regional analysis highlight the need for tailored marketing strategies.

FAQs

1. What is the projected market size of belimumab by 2031?

The belimumab market is projected to reach USD 4.3 billion by 2031, growing at a CAGR of 8.2% during the forecast period of 2024-2031[1].

2. What are the primary drivers of the belimumab market?

The primary drivers include increasing prevalence of autoimmune diseases, growing awareness and diagnosis, efficacy of belimumab, regulatory approvals, and advancements in medical research[1].

3. How does the cost-effectiveness of belimumab compare to standard care?

Studies indicate that while belimumab is costly, it provides significant health benefits, with an ICER of €22,990 and an ICUR of €32,859 per QALY in the Italian setting[4].

4. What are the main challenges facing the belimumab market?

Challenges include side effects and adverse reactions, emerging treatments, patient adherence issues, and high costs associated with the drug[1][3].

5. Which regions are expected to drive the growth of the belimumab market?

North America, particularly the United States, and the Asia-Pacific region, especially emerging economies like India and China, are expected to drive the growth of the belimumab market[1][3].

Cited Sources:

  1. Verified Market Research. Belimumab Market Size, Share, Scope, Trends, Growth & Forecast.
  2. Essay.utwente.nl. The budget impact of Belimumab SC compared to the standard of care for systemic lupus erythematosus in the Netherlands.
  3. Data Bridge Market Research. Global Belimumab Market - Industry Trends and Forecast to 2029.
  4. PLOS ONE. Assessment of the Economic Impact of Belimumab for the Treatment of Systemic Lupus Erythematosus in the Italian Setting: A Cost-Effectiveness Analysis.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.